Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise
November 24, 2025
Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep FranchiseNovember 24, 2025 Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States. With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams. Read Azurity’s press release here. The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate). Key contacts
Latest Insights
Latest NewsLatest Events
legal updates October 07, 2026 EU: Proposed KIDS Act Targets Online Child Safety guides and reports October 07, 2026 Technology, AI and the changing legal landscape of M&A guides and reports October 07, 2026 How AI is democratizing M&A for buyers and investors guides and reports October 07, 2026 Technology talent in M&A: retention, incentives and integration risk firm news October 07, 2026 Faster deals, deeper diligence: AI is transforming the legal landscape of M... firm news October 05, 2026 Leading finance partner joins Eversheds Sutherland firm news October 01, 2026 Eversheds Sutherland Switzerland appoints Dr. Michael Faske as new Partner client news September 21, 2026 |